Introduction
============

Malignant melanoma (MM), an aggressive skin cancer type, is the fifth most common cancer in males and the seventh most common cancer in females ([@b1-etm-0-0-4998]). The incidence of MM has been increasing in recent years, more rapidly than that of any other cancer type except lung cancer ([@b1-etm-0-0-4998],[@b2-etm-0-0-4998]). Accordingly, it is urgently required to develop effective strategies for MM treatment, and exploring the molecular mechanism underlying MM growth and metastasis may be promising for identifying novel therapeutic targets.

MicroRNAs (miRs) are a class of small non-coding RNAs containing 18--25 nucleotides, which act as important regulators of gene expression through binding to a recognition sequence in the 3′-UTR of their target RNAs, causing translational repression or mRNA degradation ([@b3-etm-0-0-4998],[@b4-etm-0-0-4998]). Through regulating the protein expression of their target genes, including oncogenes and tumor suppressors, numerous miRs have been demonstrated to be involved in the development and progression of various human cancer types ([@b5-etm-0-0-4998],[@b6-etm-0-0-4998]). In recent years, certain miRs have been reported to have promoting or suppressive roles in MM ([@b7-etm-0-0-4998],[@b8-etm-0-0-4998]). Among these MM-associated miRs, miR-124 has been reported to act as a tumor suppressor in MM ([@b9-etm-0-0-4998]). Zhang *et al* ([@b9-etm-0-0-4998]) indicated that treatment with physcion 8-O-β-glucopyranoside increased the expression of miR-124, which further inhibited MM cell proliferation and invasion via targeting Ral-interacting protein of 76 kDa (RLIP76). However, other important molecular targets of miR-124 in MM have remained elusive.

Versican, encoded by the VCAN gene, is a member of the aggrecan/versican proteoglycan family. It is a large chondroitin sulfate proteoglycan as well as a major component of the extracellular matrix ([@b10-etm-0-0-4998]). Previous studies have demonstrated that versican has a central role in tissue morphogenesis and embryogenesis, and participates in the regulation of cell proliferation, adhesion, migration, inflammation and angiogenesis ([@b10-etm-0-0-4998]--[@b12-etm-0-0-4998]). A previous study by our group reported that versican is a direct target gene of miR-203 and has a promoting role in the regulation of MM cell migration ([@b13-etm-0-0-4998]). However, whether any other miRs are involved in the regulation of versican expression has remained elusive.

The present study aimed to explore the underlying molecular mechanisms of the effect of miR-124 on MM growth and metastasis via regulating versican.

Materials and methods
=====================

### Clinical sample collection

The present study was approved by the Ethical Committee of the Third Xiangya Hospital of Central South University (Changsha, China). A total of 68 pairs of MM and adjacent tissues were collected during surgery between April 2007 and March 2015. Informed consent was obtained from each patient. The clinical information of the patients is summarized in [Table I](#tI-etm-0-0-4998){ref-type="table"}. Following surgical resection, the tissues were immediately frozen in liquid nitrogen and stored in it until use.

### Cell culture and transfection

The B16 mouse and A375 human MM cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). HACAT human normal skin cell line was purchased from Cell Lines Service GmbH (Eppelheim, Germany). Cells were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM) containing 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C in a humidified atmosphere containing 5% CO~2~. Cell Transfection was performed using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) in accordance with the manufacturer\'s protocol. For miR-124 functional analysis, A375 melanoma cells were transfected with scrambled miRNA (4464061) as a negative control (NC), miR-124 mimics (MC11154), negative control (NC) inhibitor (4464078) as the control for miR-124 inhibitor, or miR-124 inhibitor (AM17000) (Thermo Fisher Scientific, Inc.). For versican functional analysis, human melanoma A375 cells were transfected with pcDNA3.1-versican plasmid (34692), or empty pcDNA3.1 vector as a control (13001; both Yearthbio, Changsha, China).

### Reverse-transcription quantitative polymerase chain reaction (RT-qPCR) assay

Total RNA from tissues and cell lines was extracted with TRIzol reagent (Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocols. For miR expression analysis, the PrimeScript^®^ miRNA RT-PCR kit (RR014A; Takara, Dalian, China) was used. Real-time PCR was performed on an ABI 7500 thermocycler (Thermo Fisher Scientific, Inc.). The U6 gene was used as an internal reference. For mRNA expression detection, the TaqMan Reverse Transcription kit (N8080234; Thermo Fisher Scientific, Inc.) was used to convert RNA into complementary DNA, according to the manufacturer\'s protocol. Subsequently, the Power SYBR Green kit (4368702; Thermo Fisher Scientific, Inc.) was used to perform real-time PCR according to the manufacturer\'s protocol. GAPDH was used as an endogenous control. The following primers were used: Versican forward, 5′-GTAACCCATGCGCTACATAAAGT-3′ and reverse, 5′-GGCAAAGTAGGCATCGTTGAAA-3′; GAPDH forward, 5′-ACAACTTTGGTATCGTGGAAGG-3′ and reverse, 5′-GCCATCACGCCACAGTTTC-3′. Primers for miR-124 and U6 were purchased from Fulengen Co., Ltd. (Guangzhou, China). The reaction conditions were as follows: 95°C for 10 min, and 40 cycles of 95°C for 15 sec and 60°C for 30 sec. The relative expression was analyzed using the 2^−ΔΔCt^ method ([@b14-etm-0-0-4998]).

### Western blot analysis

Cells were lysed with ice-cold radioimmunoprecipitation assay buffer (Thermo Fisher Scientific, Inc.). The concentration of protein was quantified using a bicinchoninic acid protein assay kit (Santa Cruz Biotechnology, Inc., Dallas, TX, USA). Protein (60 µg/lane) was separated by 12% SDS-PAGE and then transferred onto a polyvinylidene difluoride membrane (Thermo Fisher Scientific, Inc.). The membrane was blocked with 5% non-fat milk (Yili, Beijing, China) in PBS for 3 h at room temperature, and then probed with rabbit anti-human versican antibody (ab19345; 1:50; Abcam, Cambridge, MA, USA) and rabbit anti-human GAPDH antibody (ab9485; 1:50; Abcam) at 4°C overnight. After washing with PBS for 3 times, the membrane was incubated with goat anti-rabbit secondary antibody (ab6721; 1:5,000; Abcam) at room temperature for 40 min. A Chemiluminescent Substrate kit (Thermo Fisher Scientific, Inc.) was used to detect signals according to the manufacturer\'s protocol. The relative protein expression, represented as the density ratio vs. GAPDH, was determined using Image-Pro plus software 6.0 (Media Cybernetics, Rockville, MD, USA).

### MTT assay

Cell proliferation was examined by an MTT assay. A375 cells (5×10^4^ cells/ml) were seeded into 96-well plates and incubated at 37°C for 24, 48 or 72 h. At 4 h prior to each time-point, 0.5% MTT solution (Thermo Fisher Scientific, Inc.) was added, followed by incubation for 4 h at 37°C. The cell supernatants were discarded and 150 µl dimethylsulfoxide was added to dissolve the formazan crystals. The optical density of each group was measured using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at a wavelength of 570 nm.

### Wound healing assay

A375 cells were cultured to full confluence. Wounds of \~1 mm width were created with a plastic scriber. Subsequently, A375 cells were washed with PBS and then incubated in serum-free DMEM at 37°C for 24 h. Subsequently, the medium was replaced with DMEM with 10% FBS, then cultured at 37°C for 24 h. The cells were then observed under a microscope and images were captured.

### Transwell assay

A Transwell assay was performed to detect the cell invasion capacity using Transwell chambers (BD Biosciences, Franklin Lakes, NJ, USA) coated with Matrigel. A suspension of A375 cells (10^6^ cells/ml) was prepared in DMEM, 300 µl of which was added into the upper chamber. Subsequently, 300 µl DMEM containing 10% FBS was added to the lower chamber. After incubated at 37°C for 24 h, the A375 cells that had not transgressed through the pores were wiped off using a cotton-tipped swab. The filters were fixed in 90% ethanol, and then stained with crystal violet (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for 10 min at room temperature. The invaded cells were counted under an inverted microscope (Olympus, Tokyo, Japan).

### Bioinformatics analysis and luciferase reporter gene assay

Targetscan software version 7.1 ([www.targetscan.org](www.targetscan.org)) was used to predict putative target genes of miR-124. The wild-type (WT) miR-124 binding sequence of the 3′-untranslated region (3′UTR) of versican was amplified from human genomic DNA from a healthy person by PCR. The mutated-type (MT) of the versican 3′UTR was generated using the Easy Mutagenesis System kit (Promega Corp., Madison, WI, USA), according to the manufacturer\'s protocol. The WT or MT of the versican 3′UTR was then sub-cloned into the downstream region of the firefly luciferase-coding region of the pMIR-GLO™ Luciferase vector (Promega Corp.). A375 cells were co-transfected with WT-versican-3′UTR or MT-versican-3′UTR reporter plasmid, and miR-124 mimics or miR-NC, using Lipofectamine 2000 according to the manufacturer\'s protocol. After transfection for 48 h, the luciferase activity was examined using the dual-Luciferase Reporter Assay System (Promega Corp.) according to the manufacturer\'s protocol.

### Statistical analysis

Values are expressed as the mean ± standard deviation. GraphPad Prism 5 software (Graphpad Software, Inc., La Jolla, CA, USA) was used to perform the statistical analysis. Differences were analyzed by using Student\'s t-test for two-group comparison and one-way analysis of variance for multiple-group comparison followed by Turkey\'s post-hoc test. The contingency data were analyzed using the chi-squared test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### miR-124 is downregulated in MM

In the present study, the miR-124 levels in MM tissues and matched adjacent non-tumorous tissues were first examined. The RT-qPCR results indicated that miR-124 was significantly downregulated in MM tissues compared with those in adjacent non-tumorous tissues ([Fig. 1A](#f1-etm-0-0-4998){ref-type="fig"}). Furthermore, the clinical significance of the expression of miR-124 in MM was assessed. Although no significant association was found between miR-124 expression and age or gender, the reduced miR-124 levels were significantly associated with the increased tumor thickness, advanced clinical stage and lymph node metastasis, although no association with gender, age or distant metastasis was identified ([Table I](#tI-etm-0-0-4998){ref-type="table"}). In addition, the miR-124 levels in B16 and A375 MM cells were examined. Normal skin HACAT cells were used as a control group. As presented in [Fig. 1B](#f1-etm-0-0-4998){ref-type="fig"}, miR-124 was also significantly downregulated in MM cell lines compared with that in HACAT cells. Accordingly, it was suggested that downregulation of miR-124 may be associated with MM progression.

### Forced expression of miR-124 decreases the proliferation, migration and invasion of A375 cells

A375 cells were then transfected with miR-NC or miR-124 mimics. RTqPCR indicated that the miR-124 levels were significantly increased after transfection with miR-124 mimics, compared with those in the miR-NC group ([Fig. 2A](#f2-etm-0-0-4998){ref-type="fig"}). An MTT assay, a wound healing assay and a Transwell assay were then performed to examine the effects of miR-124 on cell proliferation, migration and invasion, respectively. As presented in [Fig. 2B-D](#f2-etm-0-0-4998){ref-type="fig"}, forced expression of miR-124 significantly decreased the proliferation, migration and invasion of A375 cells, when compared with that in the control group.

### Versican is a novel target gene of miR-124 in A375 cells

The bioinformatics analysis predicted that miR-124 bound to a seed sequence in the 3′UTR of versican, and this targeting association was evolutionarily conserved ([Fig. 3A and B](#f3-etm-0-0-4998){ref-type="fig"}). To verify this predication, the WT and MT versican 3′UTR reporter gene plasmids were generated ([Fig. 3C](#f3-etm-0-0-4998){ref-type="fig"}). The results of the luciferase reporter gene assay indicated that the luciferase activity was significantly decreased in A375 cells co-transfected with miR-124 mimics and WT versican 3′UTR plasmid, when compared with that in the control group, but was not affected when the MT versican 3′UTR plasmid was used ([Fig. 3D](#f3-etm-0-0-4998){ref-type="fig"}). Accordingly, versican was verified as a novel target gene of miR-124 in A375 cells. The present study then assessed the effects of miR-124 on the expression of versican in A375 cells. It was revealed that forced expression of miR-124 caused a significant reduction in the protein expression of versican ([Fig. 3E](#f3-etm-0-0-4998){ref-type="fig"}). To further confirm these findings, A375 cells were transfected with miR-124 inhibitor, and non-specific miR inhibitor was used as the control group. After transfection, the miR-124 levels were significantly reduced in the miR-124 inhibitor group compared with those in the NC inhibitor group ([Fig. 3F](#f3-etm-0-0-4998){ref-type="fig"}). Furthermore, western blot analysis indicated that the protein expression of versican was significantly increased after transfection with miR-124 inhibitor compared with that in the NC inhibitor group ([Fig. 3G](#f3-etm-0-0-4998){ref-type="fig"}). Therefore, miR-124 negatively regulated the protein expression of versican in A375 cells.

### Versican is upregulated in MM

The present study then assessed the expression of versican in MM. RT-qPCR analysis indicated that the mRNA levels of versican were significantly increased in MM tissues compared with those in the adjacent non-tumorous tissues ([Fig. 4A](#f4-etm-0-0-4998){ref-type="fig"}). Further investigation revealed that the mRNA and protein expression of versican were also higher in B16 and A375 MM cells compared with those in HACAT normal skin cells ([Fig. 4B-C](#f4-etm-0-0-4998){ref-type="fig"}). Accordingly, it was indicated that versican may have a suppressive role in MM.

### Versican is involved in miR-124-mediated malignant phenotypes of A375 cells

Based on the above results, it was speculated that forced expression of miR-124 decreases the protein expression of versican, which then led to the reduced proliferation, migration and invasion of A375 cells. To clarify this speculation, miR-124-overexpressing A375 cells were then transfected with pcDNA3.1-versican open reading frame plasmid. miR-124-overexpressing A375 cells transfected with blank pcDNA3.1 vector were used as the control group. After transfection, the mRNA and protein expression of versican were significantly higher in the miR-124+versican group compared with those in the miR-124+NC group ([Fig. 5A and B](#f5-etm-0-0-4998){ref-type="fig"}). MTT, wound healing and Transwell assays were then performed to examine the effect on cell proliferation, migration and invasion, respectively. As presented in [Fig. 5C-E](#f5-etm-0-0-4998){ref-type="fig"}, the proliferation, migration and invasion of A375 cells were significantly upregulated in the miR-124+versican group compared with those in the miR-124+NC group. Therefore, versican acts as a downstream effector of miR-124 in mediating the malignant phenotypes of A375 cells. miR-124 is likely to inhibit the malignant phenotypes of A375 cells, at least in part, through directly targeting versican.

Discussion
==========

The regulatory mechanisms of miR-124 in MM have remained largely elusive. The present demonstrated that miR-124 was significantly downregulated in MM, which was associated with the aggressive progression of MM. Restoration of miR-124 suppressed the proliferation, migration and invasion of A375 cells. Furthermore, versican was identified as a novel target of miR-124. The expression of versican was upregulated in MM tissues and cell lines, and it was identified to be negatively regulated by miR-124 in A375 cells. In addition, overexpression of versican impaired the suppressive effects of miR-124 on the malignant phenotypes of A375 cells.

Deregulation of miR-124 has been implicated in certain common types of human cancer ([@b15-etm-0-0-4998]--[@b17-etm-0-0-4998]). For instance, miR-124 is significantly downregulated in osteosarcoma, where it is associated with malignant progression as well as poor prognosis ([@b17-etm-0-0-4998]). In addition, miR-124 was reported to has a suppressive effect on osteosarcoma cell proliferation, invasion and migration, and promoted their apoptosis ([@b17-etm-0-0-4998]). Recently, Zhang *et al* ([@b9-etm-0-0-4998]) reported that miR-124 was significantly downregulated in MM and functioned as a tumor suppressor via targeting RLIP76. The present study also revealed that miR-124 was significantly downregulated in MM tissues and cell lines, when compared with that in matched adjacent non-tumorous tissues and normal skin cells, respectively. In addition, the present study demonstrated that low miR-124 expression was significantly associated with the tumor thickness, clinical stage and lymph node metastasis, which suggested that its downregulation may contribute to the malignant progression of MM. An *in vitro* experiment revealed that forced expression of miR-124 effectively reduced the proliferation, migration and invasion of MM cells, suggesting that miR-124 is likely to have a suppressive role in MM growth and metastasis, and miR-124 mimics may be used as a potential candidate for MM treatment.

As miRs function through negatively regulating the protein expression of their target genes ([@b18-etm-0-0-4998]), the present study further focused on the putative targets of miR-124 in MM cells. A bioinformatics analysis predicted that miR-124 binds to a seed sequence in the 3′UTR of versican mRNA. Versican has been demonstrated to be aberrantly upregualted in human cancers, including breast and prostate cancer, and to have a promoting role in cancer cell proliferation, migration and invasion ([@b19-etm-0-0-4998],[@b20-etm-0-0-4998]). Overexpression of peritumoral versican was previously identified in superficially spreading MM, and the expression of versican was intensely positive in primary and metastatic MM ([@b21-etm-0-0-4998],[@b22-etm-0-0-4998]). In addition, knockdown of versican inhibited the proliferation and migration of MM cells, while it promoted MM-cell adhesion to type I collagen, laminin and fibronectin, suggesting that versican may become a promising therapeutic target for treating MM ([@b23-etm-0-0-4998]). As the present study identified versican as a putative target gene of miR-124, it was speculated that miR-124 may have a suppressive role in MM through inhibition of versican. To verify this speculation, a luciferase reporter gene assay was performed, the findings of which confirmed that versican was indeed a target gene of miR-124 in MM cells. Subsequently, the expression of versican was assessed in MM, revealing that versican is upregulated in MM tissues and cell lines. To further clarify the regulatory association between miR-124 and versican, a number of loss- and gain-of-function experiments were performed. It was revealed that overexpression of miR-124 reduced the protein expression of versican, while knockdown of miR-124 expression increased the versican protein levels in MM cells. These results suggested that the upregulation of versican in MM is at least partly due to the downregulation of miR-124.

Since the present study revealed that miR-124 negatively regulated the protein expression of versican in MM cells, it was then assessed whether versican was involved in the suppressive effects of miR-124 on the malignant phenotypes of MM cells. Overexpression of versican was identified to impair the inhibitory effects of miR-124 upregulation on the proliferation, migration and invasion of MM cells. These results confirmed that miR-124 acts as a tumor suppressor in MM, at least partly through directly inhibiting the protein expression of versican.

In addition, several other miRs have also been demonstrated to directly target versican, such as miR-138 and miR-199a ([@b24-etm-0-0-4998],[@b25-etm-0-0-4998]). Furthermore, a previous study by our group reported that versican was also a target gene of miR-203 in MM, and was involved in the miR-203-mediated migration of MM cells ([@b13-etm-0-0-4998]). Therefore, the present findings expanded the current understanding of the regulatory mechanism of miR/versican signaling in MM.

In conclusion, the present study was the first, to the best of our knowledge, to demonstrate that versican is a novel target gene of miR-124, which in turn had suppressive effects on the malignant phenotypes of MM cells, at least partly via targeting versican. Accordingly, the present study expanded the current understanding of the molecular mechanisms underlying MM progression, which may promote the development of promising therapeutic strategies for MM.

![Expression of miR-124 (A) in MM tissues and their matched adjacent tissues and (B) in the B16 mouse and A375 human MM cell lines and HACAT human normal skin cells detected by reverse-transcription quantitative polymerase chain reaction analysis. \*\*P\<0.01 vs. adjacent or HACAT. MM, malignant melanoma; miR, microRNA.](etm-14-04-3555-g00){#f1-etm-0-0-4998}

![A375 cells were transfected with miR-NC or miR-124 mimics. (A) Reverse-transcription quantitative polymerase chain reaction analysis was used to examine the expression of miR-124. (B) MTT assay, (C) wound healing assay (magnification, ×40) and (D) Transwell assay (magnification, ×200) were used to examine cell proliferation, migration and invasion, respectively. \*\*P\<0.01 vs. miR-NC. miR, microRNA; miR-NC, scrambled negative control miR mimics.](etm-14-04-3555-g01){#f2-etm-0-0-4998}

![(A and B) A bioinformatics analysis demonstrated the putative seed region of miR-124 in the wild-type 3′-UTR of versican, and their target association is evolutionarily conserved. (C) The WT and MT versican 3′-UTR reporter gene plasmids were generated. (D) Luciferase reporter gene assay results. (E) Western blot analysis was performed to examine the protein expression of versican in A375 cells transfected with miR-NC or miR-124 mimics. (F) Knockdown of miR-124 was confirmed by reverse-transcription quantitative polymerase chain reaction analysis. (G) Western blot analysis was performed to examine the protein expression of versican in A375 cells transfected with miR-124 inhibitor or NC inhibitor. \*\*P\<0.01 vs. control, miR-NC or NC inhibitor. UTR, untranslated region; WT, wild-type; MT mutated; miR, microRNA; miR-NC, scrambled negative control miR mimics; VCAN, versican.](etm-14-04-3555-g02){#f3-etm-0-0-4998}

![(A) RT-qPCR analysis was used to examine the mRNA expression of versican in MM tissues and matched adjacent tissues. (B) RT-qPCR and (C) western blot were used to examine the mRNA and protein expression of versican in the B16 mouse and A375 human MM cell lines and HACAT human normal skin cells. \*\*P\<0.01 vs. adjacent or HACAT. RT-qPCR, reverse-transcription quantitative polymerase chain reaction. MM, malignant melanoma; miR, microRNA.](etm-14-04-3555-g03){#f4-etm-0-0-4998}

![miR-124-overexpressing A375 cells were transfected with pcDNA3.1-versican open reading frame plasmid or blank pcDNA.31 vector as an NC. (A) Reverse-transcription quantitative polymerase chain reaction analysis and (B) western blot were used to assess the mRNA and protein expression of versican, respectively. (C) MTT assay, (D) wound healing assay (magnification, ×40) and (E) Transwell assay (magnification, ×200) were used to examine cell proliferation, migration and invasion, respectively. \*\*P\<0.01 vs. miR-124+NC. NC, negative control; miR, microRNA.](etm-14-04-3555-g04){#f5-etm-0-0-4998}

###### 

Association between the miR-124 expression and clinicopathological features in patients with malignant melanoma (n=68).

                                miR-124 expression                
  ------------------------ ---- -------------------- ------------ -----------------------------------------------------
  Gender                                                          0.468
    Male                   39   19 (48.7)            20 (51.3)    
    Female                 29   17 (58.6)            12 (41.4)    
  Age (years)                                                     1.000
    ≤60                    33   17 (51.5)            16 (48.5)    
    \>60                   35   19 (54.3)            16 (45.7)    
  Tumor thickness (mm)                                            0.007^[a](#tfn1-etm-0-0-4998){ref-type="table-fn"}^
    ≤1                     30   10 (33.3)            20 (66.7)    
    \>1                    38   26 (68.4)            12 (31.6)    
  Clinical stage                                                  0.013^[b](#tfn2-etm-0-0-4998){ref-type="table-fn"}^
    I/II                   27     9 (33.3)           18 (66.7)    
    III/IV                 41   27 (65.9)            14 (34.1)    
  Lymph node involvement                                          0.014^[b](#tfn2-etm-0-0-4998){ref-type="table-fn"}^
    No                     29   10 (34.5)            19 (65.5)    
    Yes                    39   26 (66.7)            13 (33.3)    
  Distant metastasis                                              0.57
    No                     49   22 (44.9)            27 (55.1)    
    Yes                    19   14 (73.7)              5 (26.3)   

P\<0.01

P\<0.05. miR, microRNA.
